Universal Ibogaine (FRA:JC4) 3-Year RORE % : 0.00% (As of Apr. 2025)


What is Universal Ibogaine 3-Year RORE %?

Universal Ibogaine FRA:JC4 3-Year RORE % is 0.00 as of Apr. 2025.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Universal Ibogaine's 3-Year RORE % for the quarter that ended in Apr. 2025 was 0.00%.

The industry rank for Universal Ibogaine's 3-Year RORE % or its related term are showing as below:

FRA:JC4's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -11.44
* Ranked among companies with meaningful 3-Year RORE % only.

Universal Ibogaine  (FRA:JC4) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

Universal Ibogaine 3-Year RORE % Related Terms

Universal Ibogaine 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine 3-Year RORE % Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
3-Year RORE %
Get a 7-Day Free Trial -53.49 42.42 0.00 0.00 -50.72

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -50.72 -35.42 -31.71 -27.78

FRA:JC4 vs LABT, CALC, LNAI: 3-Year RORE % Comparison

For the Biotechnology subindustry, Universal Ibogaine's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's 3-Year RORE % falls into.


Universal Ibogaine 3-Year RORE % Calculation

Universal Ibogaine's 3-Year RORE % for the quarter that ended in Apr. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.013--0.023 )/( -0.036-0 )
=0.01/-0.036
=-27.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 0.00 mean?
Universal Ibogaine (FRA:JC4) has a 3-Year RORE % of 0.00 as of Apr. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's 3-Year RORE % too high?
Universal Ibogaine's current 3-Year RORE % is 0.00.
How does Universal Ibogaine's 3-Year RORE % compare to LABT and CALC?
Universal Ibogaine's 3-Year RORE % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (FRA:JC4) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Universal Ibogaine (FRA:JC4), the current 3-Year RORE % is 0.00 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.